Study Title: A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus- Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Kaczmar, John, at kaczmar@musc.edu, or please call +1 843-792-6691.Study Coordinator, Langley, Madelyn, at langlema@musc.edu.Trial opened at the following institutions: Medical University of South Carolina